Improving strategies for the diagnosis of cardiac amyloidosis

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Amyloidosis refers to a group of rare but potentially fatal, protein misfolding diseases. The heart is frequently involved in the most common types, that is, immunoglobulin light chain and transthyretin amyloidosis and is the single most important predictor of patient outcomes. A major limitation in improving patient outcomes, in addition to developing novel therapeutics, is the late diagnosis of the disease. Once suspected, an organ for biopsy should be targeted and the amyloid type should be identified by mass spectrometry. An endomyocardial biopsy should be offered if cardiac involvement is in doubt. Echocardiography, MRI and nuclear imaging can provide valuable diagnostic and prognostic information and can secure the diagnosis if amyloid has been identified in an extracardiac tissue.

Original languageEnglish (US)
Pages (from-to)945-961
Number of pages17
JournalExpert Review of Cardiovascular Therapy
Volume13
Issue number8
DOIs
StatePublished - Aug 1 2015

Fingerprint

Amyloidosis
Amyloid
Proteostasis Deficiencies
Immunoglobulin Light Chains
Biopsy
Delayed Diagnosis
Echocardiography
Mass Spectrometry
Therapeutics
Amyloidosis, Hereditary, Transthyretin-Related

Keywords

  • amyloidosis
  • heart failure
  • heart failure with preserved ejection fraction
  • immunoglobulin free light chains
  • infiltrative cardiomyopathies
  • transthyretin

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Improving strategies for the diagnosis of cardiac amyloidosis. / Kourelis, Taxiarchis; Gertz, Morie.

In: Expert Review of Cardiovascular Therapy, Vol. 13, No. 8, 01.08.2015, p. 945-961.

Research output: Contribution to journalReview article

@article{e9254ae2de4b4abcb783b1a99744b98b,
title = "Improving strategies for the diagnosis of cardiac amyloidosis",
abstract = "Amyloidosis refers to a group of rare but potentially fatal, protein misfolding diseases. The heart is frequently involved in the most common types, that is, immunoglobulin light chain and transthyretin amyloidosis and is the single most important predictor of patient outcomes. A major limitation in improving patient outcomes, in addition to developing novel therapeutics, is the late diagnosis of the disease. Once suspected, an organ for biopsy should be targeted and the amyloid type should be identified by mass spectrometry. An endomyocardial biopsy should be offered if cardiac involvement is in doubt. Echocardiography, MRI and nuclear imaging can provide valuable diagnostic and prognostic information and can secure the diagnosis if amyloid has been identified in an extracardiac tissue.",
keywords = "amyloidosis, heart failure, heart failure with preserved ejection fraction, immunoglobulin free light chains, infiltrative cardiomyopathies, transthyretin",
author = "Taxiarchis Kourelis and Morie Gertz",
year = "2015",
month = "8",
day = "1",
doi = "10.1586/14779072.2015.1069181",
language = "English (US)",
volume = "13",
pages = "945--961",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "8",

}

TY - JOUR

T1 - Improving strategies for the diagnosis of cardiac amyloidosis

AU - Kourelis, Taxiarchis

AU - Gertz, Morie

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Amyloidosis refers to a group of rare but potentially fatal, protein misfolding diseases. The heart is frequently involved in the most common types, that is, immunoglobulin light chain and transthyretin amyloidosis and is the single most important predictor of patient outcomes. A major limitation in improving patient outcomes, in addition to developing novel therapeutics, is the late diagnosis of the disease. Once suspected, an organ for biopsy should be targeted and the amyloid type should be identified by mass spectrometry. An endomyocardial biopsy should be offered if cardiac involvement is in doubt. Echocardiography, MRI and nuclear imaging can provide valuable diagnostic and prognostic information and can secure the diagnosis if amyloid has been identified in an extracardiac tissue.

AB - Amyloidosis refers to a group of rare but potentially fatal, protein misfolding diseases. The heart is frequently involved in the most common types, that is, immunoglobulin light chain and transthyretin amyloidosis and is the single most important predictor of patient outcomes. A major limitation in improving patient outcomes, in addition to developing novel therapeutics, is the late diagnosis of the disease. Once suspected, an organ for biopsy should be targeted and the amyloid type should be identified by mass spectrometry. An endomyocardial biopsy should be offered if cardiac involvement is in doubt. Echocardiography, MRI and nuclear imaging can provide valuable diagnostic and prognostic information and can secure the diagnosis if amyloid has been identified in an extracardiac tissue.

KW - amyloidosis

KW - heart failure

KW - heart failure with preserved ejection fraction

KW - immunoglobulin free light chains

KW - infiltrative cardiomyopathies

KW - transthyretin

UR - http://www.scopus.com/inward/record.url?scp=84937605900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937605900&partnerID=8YFLogxK

U2 - 10.1586/14779072.2015.1069181

DO - 10.1586/14779072.2015.1069181

M3 - Review article

C2 - 26174181

AN - SCOPUS:84937605900

VL - 13

SP - 945

EP - 961

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 8

ER -